boston narrow moat remain solid rais
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
regain foot one three major
cardiac devic maker left acquisition-rel
oper mishap earlier manag team behind
think firm abil emerg nearli decad upheav
underscor tough competitor boston well
difficult new competitor establish foothold
highli consolid devic market ceo michael
mahoney firm focus introduc meaning
innov leverag boston histor formid sale
market resourc
mahoney shift boston away earlier relianc
tradit cardiac rhythm manag stent busi
larg matur point focu new
technolog boston tap novel platform includ
eluvia stent peripher use subcutan
defibril left atrial appendag closur atrial fibril
product even market face slower growth boston
bolster signific presenc consist introduc new
product exampl boston maintain strong posit
drug-coat coronari stent
develop
transcathet mitral valv repair technolog -- build
boston footprint cardiac vascular market despit
trail cardiac rhythm manag boston remain
game launch compar mri-saf devic
quadripolar lead
remain favor boston return transcathet
aortic valv market lotu devic new acur tavr
product addit male urolog portfolio
long view
moatiest part am busi big question whether
boston wide-rang presenc across devic categori
enough maintain posit especi competitor
includ abbott seek
consolid order solidifi place hospit vendor
would surpris competit medic technolog
compani may eye boston
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
produc less-invas medic devic insert
human bodi small open cut manufactur
product use angioplasti blood clot filtrat cardiac rhythm
diseas upper gastrointestin tract test treatment incontin
firm market devic healthcar profession institut
global foreign sale account nearli half firm total sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
modestli rais fair valu estim
per share reflect cash flow realiz sinc last
updat remain bullish watchman left atrial
appendag closur devic return lotu tavr
market increas adopt s-icd
continu hold rel optimist project
boston growth beyond explicit forecast period base
firm pipelin promis technolog includ
acur tavr eluvia drug-coat stent peripher
use new electrophysiolog navig platform
midterm expect averag annual top-lin
growth fuel primarili
cardiovascular med-surg segment addit
btg manag effort streamlin oper
enhanc effici taken hold forecast
increas roughli basi point adjust oper
margin sell market cost risen
last year order support plan product
launch howev expect sg slightli moder
come year new product see greater
base higher averag volatil cash flow
on-go exposur product liabil claim rate
uncertainti high
bear-cas scenario place share
assum long-term data boston watchman devic
diminish demand left atrial appendag closur
devic lotu transcathet valv unabl gain
substanti ground edward
tavr market scenario includ slow eros
boston coronari stent franchis subcutan
adopt fall short expect assum
clinic efficaci ablat atrial fibril
disappoint urolog sling penil implant revenu
growth slow cost share increas anem
perform higher-margin busi boston
oper margin would match histor adjust
margin
bull case would rais fair valu estim
per share assum boston see robust uptak
watchman penil implant catheter-bas ablat
lotu valv new intervent oncolog
platform averag annual revenu growth exceed
next five year thank disciplin
think boston sport narrow moat firmli root
intang asset boston benefit cach
patent cover variou product although
intellectu properti necessarili
lock
competitor year pharmaceut asset
shield firm competit base primarili
price boston along medic devic compani
aggress defend intellectu properti
intellectu properti right violat
result sale injunct competitor requir
stop sell product near midterm
pose setback peer compani must revisit
draw board redesign product way
infring exist patent longer term
howev devic manufactur usual invent way
around patent
boston also enjoy extens network relationship
practition -- anoth basi moat boston still
own signific footprint stent electrophysiolog
endoscopi urolog neuromodul intervent
cardiolog radiolog devic stent busi strike
us least moati consid quick learn curv
gener substitut brand howev
devic area gener steeper
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
boston necessarili first-to-market key
emerg technolog set drive growth
cardiac market next five year think
innov differenti enough allow firm
market
manag left atrial appendag closur devic
drug-coat peripher balloon addit think
purchas rival st jude medic abbott could lead
weaker pipelin abbott continu nurtur st
jude cultur innov final note threat
new entrant remain low especi consid
regulatori approv
gain
learn curv requir greater invest
practition use well make less like devic
use interchang competit brand
final cardiac medic devic industri structur
way make highli unlik new market
entrant could come edg boston small
start-up like purchas bigger fish
technolog pan oligopoli strengthen
boston custom base rel
fragment hospit less abl exert
bargain power cardiac devic maker
note coronari stent market seem
stabl three competitor field -- price
declin older product becom pronounc
four player game may one reason
johnson johnson exit coronari stent market
late
firm competit stand solid base intern
develop product well novel acquir technolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oboston remain one top player come
intellectu properti medic technolog
arena bode well abil innov
enough keep rival
oboston breadth product emphasi
differenti put compani firm foot
supplier hospit
oboston coronari stent busi less moati
cardiac rhythm manag segment
oboston busi unlik return double-
digit growth long physician remain hamper
current implant guidelin dearth
diagnost test accur identifi sudden
oboston recent acquisit put firm
leadership role sever nich market
includ leadless icd bronchialthermoplasti
oboston like second third market
key emerg technolog drive growth
cardiac devic next five year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
increas debt leverag acquir
new product reduc debt
increas late accommod
impend acquisit btg juli compani held
million cash compar billion long-term
debt expect firm exit year
debt/ebitda around time firm financ
billion plan acquisit btg primarili cash
hand addit debt boston key debt matur
next year includ billion due
anoth million earli firm
issu billion due proce primarili
earmark buy back million debt near matur
compani suspend share repurchas program
help de-lever pay dividend
howev surpris share repurchas
restart midterm
base higher-than-averag volatil cash flow
on-going exposur product liabil claim rate
boston scientif uncertainti high think
manag put boston trail qualiti
alway face possibl devic defect product
recal exampl boston reach tail end
settlement transvagin mesh product firm
set asid nearli billion cover liabil relat
matter think boston may need increas
reserv base number claimant
recent settlement amount thank healthcar reform
hurdl secur reimburs technolog
add-on payment risen boston need invest
clinic studi demonstr superior outcom
and/or cost save order establish reimburs
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
think boston stewardship standard base current
ceo michael mahoney influenc boston perform
last four year mahoney bring impress devic
experi johnson johnson focus
repopul firm pipelin re-energ firm
focu meaning innov think new team
helm provid boston clean slate like
capit alloc decis
shareholder-friendli especi contrast former ceo
jim tobin expens pursuit guidant
mahoney approach alloc invest
much prudent eye disciplin manner
pleas tuck-in acquisit adjac field
strengthen boston portfolio key therapeut area
instanc boston acquisit securu medic
make thermal monitor equip good fit
boston cardiac ablat cathet firm also
acquir sadra medic lotu tavr symeti acur
tavr soon integr btg intervent
ceo/chairman board/
repres date owner name posit common share held report holder issuer
new york mellon corp
fidel manag research compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
strength innov help boston scientif
sustain solid perform seen jul
post anoth quarter solid result
gener met expect top bottom line
havent made substanti adjust
assumpt like increment increas fair
valu reflect cash flow realiz sinc last updat
perspect long consid boston narrow
econom moat stronger end spectrum
compar exampl integra lifesci whose
narrow moat isnt strong view firm
continu demonstr strength innov
commerci novel technolog think would
worthwhil revisit examin boston moat
consid whether merit upgrad
despit soft spinal cord stimul
come particularli strong prior-year period
quarterli growth intervent cardiolog peripher
intervent endoscopi constant currenc
expect solid growth sustain thank roll
transcathet aortic valv lotu edg launch
left atrial appendag devic watchman japan on-go
adopt subcutan implant cardiovert
defibril peripher stent think impend
addit btg intervent oncolog portfolio
add growth potenti
boston load pipelin wide rang
product across therapeut area anticip
commerci lotu edg accur neo tavr
devic particularli signific driver firm
although lotu unabl displac market leader
edward europ carv
respect share market think abil
reposit valv less frequent need perman
pacemak could entic intervent cardiologist
tri lotu
boston scientif post solid first quarter
hold steadi fair valu estim apr
first-quart result gener met expect
exchang headwind stronger wed anticip
boston quarterli oper revenu growth
consist weve estim year
firm kept tight grip expens profit
boost settlement payment edward
lifesci sever key new product launch
deck remain confid boston narrow moat
pleas see boston receiv fda approv
lotu edg tavr
replac product april hadnt expect
fall initi domest lotu launch underway
anticip strong interest tri product
especi consid uniqu mechan deploy
devic abil reposit valv whether
firm perman captur market share remain open
question expect carv nich posit
especi certain complex patient third tavr
competitor enter market pressur
abbott portico devic isnt like launch
earli consid track record clinic data
behind edward sapien corevalv along
differenti lotu pessimist
portico becom peripher competitor
clear whether recent unfavor analysi
paclitaxel-co balloon temporari damper dcb
drug-coat balloon usag someth perman
consid paclitaxel coat use balloon
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
boston solid result stand contrast constant
currenc declin abbott saw busi
driven declin market eager
see medtron busi fare
particular whether push risk-bas contract
tyrx envelop ensu product pull-through
offer degre insul competitor
stent year seemingli problem
clinic data somewhat startl nevertheless dcb
market leader -- medtron inpact admir becton
lutonix -- also coat paclitaxel practition
respons like affect entir categori
come
coupl issu first quarter caught
attent underscor view boston abil
innov put firm strong competit posit
although rival yet report recent
quarterli perform boston certainli outperform
abbott sever count first boston rack
quarterli growth spinal cord stimul product line
recogn slower market
typic grow low doubl digit mid-teen
perform roll wavewrit translat
nearli growth year year convers abbott
saw neuromodul busi declin constant
currenc first quarter dismal perform
partial reflect departur abbott salesforc
think effect exacerb wane
abbott neuromod product cycl abbott manag
indic two new pain manag system launch
late earli would earliest wed
expect current situat chang boston alreadi
brace competit gather data
wavewrit work improv product perform
second half
grew respect first quarter consid
matur tradit market becom growth
low- mid-single-digit rang solid think
perform suggest high level execut
salesforc boston tradit crt-d product
line along continu adopt s-icd
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
